No Data
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Express News | BridgeBio Pharma Says The Continued Curve Separation Of The Composite Endpoint Of ACM And Recurrent Cardiovascular-Related Hospitalizations Emphasizes The Importance Of Early Intervention Resulting In Early And Sustained Clinical Benefits, With...
BridgeBio Pharma Presented Initial Outcomes From The ATTRibute-CM Open-label Extension Study Of Acoramidis In ATTR-CM At The AHA Scientific Sessions; Acoramidis Demonstrated The Earliest Known Time To Separation In Cardiovascular Outcomes In The...
Express News | BridgeBio Pharma Inc - Acoramidis Well Tolerated With No New Safety Signals in Long-Term Evaluation
Express News | Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
BridgeBio's Achondroplasia Treatment Shows 18-Month Results, Published in NEJM
No Data
No Data
